No Data
No Data
Getein Biotech, Inc (603387.SH) annual equity distribution for 2023: 0.1 yuan per share. Registration of equity on June 11th.
Getein Biotech, Inc. (603387.SH) released an announcement on the implementation of the annual equity distribution plan for 2023, which was made public prior to the implementation of the plan...
Foundation Egg Biotech (603387.SH) announced first-quarter results, net profit of 86.013,500 yuan, a year-on-year decrease of 29.22%
Foundation Egg Biotech (603387.SH) released its report for the first quarter of 2024. The company achieved operating income of 3 during the reporting period...
Is Weakness In Getein Biotech, Inc (SHSE:603387) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?
Getein Biotech, Inc (SHSE:603387) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough
Retail Investors Among Getein Biotech, Inc's (SHSE:603387) Largest Stockholders and Were Hit After Last Week's 8.1% Price Drop
BaseEgg Biology (603387.SH): The current luminescence collection project in Anhui accounts for a small proportion of the company's current luminescence reagent project revenue
On November 8, Gelonghui (603387.SH) said at the online performance briefing that judging from the company's chemiluminescence reagent revenue structure, the myocardial category accounts for 85%, and inflammation and tumors account for about 10% in total. At this stage, chemiluminescence mainly focuses on myocardial and inflammation tests. In the future, with the gradual coverage of small assembly line installations, it will drive an increase in testing items such as infectious diseases, hypertonics, and tumors. This time, the Anhui luminescence collection project accounts for a small proportion of the company's current luminescence reagent project revenue, and has little impact on the company's chemiluminescence business.
No Data